SAN DIEGO — Among patients with moderate to very severe COPD receiving tezepelumab vs. placebo, the annualized rate of exacerbations dropped by 17%, according to research presented at the American Thoracic Society International Conference.“Tezepelumab is a monoclonal antibody that specifically blocks [thymic stromal lymphopoietin] from interacting with its receptor,” Dave Singh,